Table 3.
Patient Characteristics According to Ras Mutation or Wild-Type
Ras Mutant N = 14 |
Non-Ras Mutant N = 24 |
P Value | |
---|---|---|---|
Median age (years) | 58.5 | 39.5 | .220 |
Range | (28-68) | (25-76) | |
Mean age | 53.7 | 47.1 | |
FIGO stage | |||
I | 3 (21.4%) | 1 (4.2%) | .105 |
II | - | - | |
III | 7 (50%) | 21 (87.5%) | |
IV | 4 (28.6%) | 2 (8.3%) | |
Surgery | |||
Primary debulking | 7 (50%) | 18 (75%) | .163 |
Interval debulking | 7 (50%) | 6 (25%) | |
Residual tumor | |||
R0 | 11 (78.6%) | 22 (91.7%) | .337 |
R > 1 | 3 (21.4%) | 2 (8.3%) | |
R0-1 | - | - | |
Association of borderline component | 6 (42.9%) | 12 (50%) | .745 |
Initial systemic treatment | |||
Platinum-based chemo | 13 (92.9%) | 24 (100%) | .368 |
Hormonal treatment | 1 (7.1%) | - | - |
Bilateral | 9 (64.3%) | 19 (79.2%) | .217 |
Unilateral | 5 (35.7%) | 3 (12.5%) | |
Unknown | - | 2 (8.3%) | |
Lymph node involvement | |||
Yes | 6 (42.9%) | 9 (37.5%) | |
No | 8 (57.1%) | 15 (62.5%) | |
Ascites | |||
Yes | 6 (42.9%) | 4 (16.7%) | 1.000 |
No | 8 (57.1%) | 19 (79.2%) | |
Unknown | - | 1 (4.2%) |